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Abstract
Recommendations for urgent reversal of oral anticoagulation with vitamin K1 antagonists are largely
derived from case series employing empirical dosing regimens with vitamin K1 and prothrombin
complex concentrates. Data on the use of prothrombin complex concentrates in this indication are
scarce in the elderly who are at high risk of both hemorrhagic and thrombotic complications. The
two cases presented here describe patients older than 75 years who underwent rapid International
Normalized Ratio (INR) reversal with prothrombin complex concentrates for surgical treatment
of a bleeding ruptured spleen and for emergency surgery of a dissecting aorta. Both patients had
their INRs rapidly corrected to ≤ 1.6 and underwent operation without complications. Evidence
on treatment of patients who present with elevated INR and who have major bleeding or need to
undergo emergency surgery is based mainly on observational studies. The two elderly patients
presented here underwent successful emergency surgery after their INRs had been corrected with
the intravenous use of vitamin K1 in combination with prothrombin complex concentrate that was
administered according to current guideline recommendations.
Background
For "over-anticoagulation" associated with major bleed-
ing or in the case of reversal for emergency surgey in
patients orally anticoagulated with coumarin or related
vitamin K1 antagonists, administration of vitamin K1 is
inadequate, since its full effect occurs after 12 to 24 hours.
The volume of plasma required for reversal is almost
invariably too large to be infused safely, whereas pro-
thrombin-complex concentrates (PCC) are effective and
convenient [1,2]. These products are virally inactivated
and therefore safer than plasma with respect to the trans-
mission of viral diseases, but a thrombogenic effect has
occasionally been reported; as bleeding complications are
more prevalent in orally anticoagulated elderly patients, a
lack of published data on the clinical use of PCC in the
elderly may even be more relevant regarding its safety [3-
5]. Some randomised controlled studies on the safety of
administering a PCC to urgently reverse the anticoagulant
effects of vitamin K1 antagonists to normalize INRs sup-
port the recommendations of consensus guidelines devel-
oped by various task forces and expert panels that PCCs
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are the agents of choice for urgent vitamin K1 antagonist
reversal [3].
We describe our experience with two patients older than
75 years of age in whom PCC was used for immediate cor-
rection of their INRs before undergoing major cardiotho-
racic and abdominal emergency surgery.
Cases
Patient 1
A 80 year-old patient receiving coumarin for atrial fibrilla-
tion, arterial hypertension and diabetes mellitus was
admitted to our hospital because of left-sided thoraco-
abdoiminal pain. Initial evaluation ruled out coronary
artery disease. An electrocardiogram on admission dem-
onstrated atrial fibrillation at a rate of 145 beats per
minute. There was no hematemesis or melena. Presence of
low-grade fever and non-productive cough, and the phys-
ical examination suggested lower airway infection which
was confirmed by chest radiography. Blood tests revealed
anemia with hemoglobin 10.4 g/dL and hematokrit
31.4%, leukocytosis of 10,600 G/L and an elevated C-
reactive protein of 14.9 mg/dL. Under long-term oral anti-
coagulation with coumarin an actual INR of 2.96 was
determined. His pain presented with slow onset and was
aggravated by respiration suggesting its pleural origin due
to lower respiratory tract infection. As after 48 hours pain
was continuously present and now independent of respi-
ration, additional imaging studies were performed.
Abdominal ultrasonography and computerized tomogra-
phy identified splenomegaly with inhomogenous paren-
chymal structure compatible with splenic hemorrhage.
Hemodynamically stable his hemoglobin had dropped to
8.3 g/dL. Therefore PCC ("Uman Complex®"; Kedrion
Spa., Castelvecchio Pascoli, Italy) at a dose of 50 IU per kg
body weight were administered i.v. in combination with
10 mg of vitamin K1. At three and a half hours after PCC
infusion, the INR was 1.5 and emergency splenectomy
was performed. Surgical intervention and postoperative
course were uncomplicated with no signs and symptoms
of venous or arterial thromboembolism. The patient was
discharged after oral anticoagulation had been reinsti-
tuted.
Patient 2
A 77-year-old man without a particular family history but
with a past medical history of peripheral arterial occlusive
disease that was surgically treated including long-term
oral anticoagulation with coumarin presented with sud-
den onset chest discomfort at rest. He was admitted to our
hospital. Hemodynamics were stable. There were no rales
or heart murmurs, except S4 of the heart sound. Electro-
cardiography showed sinus rhythm with non-specific ST-
segment changes in leads I, II, aVL, aVF and V3–6. Arterial
blood pressure was 130/100 mmHg on the right arm and
110/60 mmHg on the left. The chest pain initiated with a
blow and then migrated toward the lumbar area over
time. Chest X-ray was unremarkable but contrast com-
puted tomography confirmed aortic dissection from the
ascending aorta to the abdominal aorta. Stanford type A
aortic dissection with a possible tear entry near the aortic
arch was diagnosed. The patient was oliguric 8 hours after
admission. No other symptoms suggesting cerebral, spi-
nal or peripheral perfusion deficits or hematoma forma-
tion were present. Laboratory examination identified
elevated D-dimer levels and an INR of 3.44; other blood
tests including cardiac markers and renal function tests
were normal. PCC at a dose of 45 IU per kg body weight
were administered i.v. in combination with 10 mg of vita-
min K1. He was then transferred to Verona University Hos-
pital approximately 10 h after the onset. Two and a half
hours after intravenous administration of PCC the INR
was 1.6. Emergency graft replacement of the ascending
aorta was performed. Surgical therapy was performed
without complication and the postoperative clinical
course was uneventful. Renal other organ functions
remained normal and unaffected, respectively. The
patient was transferred to his home hospital in Germany
on the 6th postoperative day in stable condition after oral
anticoagulation with coumarin was again begun.
Discussion
The two cases presented here describe orally anticoagu-
lated patients over 75 years of age whose prolonged INRs
were corrected with PCCs for surgical treatment of a
bleeding ruptured spleen and for emergency surgery of a
dissecting aorta. Both patients had their INRs corrected to
below 1.5 and underwent operation without excessive
bleeding or thromboembolic events.
Limitations in the use of PCC for anticoagulant reversal
include the elderly because many studies reported orally
anticoagulated patients mainly <75 years of age who are
at lower risk of both, bleeding as well as atherothrombotic
complications [5]. Current recommendations for emer-
gency anticoagulant reversal apply to adult patients inde-
pendent of age [1-4]. In the two presented cases with
patients of > 75 years of age, PCC was effective and safe in
reversing oral anticoagulation.
As the INR increases with oral anticoagulation, it has been
assumed that any approach to the normalization of
increased INRs is equivalent to reversal of the anticoagu-
lant effect and the re-establishment of normal hemostasis.
Even though the various strategies and therapeutic agents
available to achieve this goal have rarely been compared
in head-to-head randomized controlled clinical trials,
case series including reports like this one are in support of
using INR as a valid surrogate marker for corrected
hemoastasis.Thrombosis Journal 2007, 5:1 http://www.thrombosisjournal.com/content/5/1/1
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Thrombotic episodes have been reported with PCC when
they have been used to cover surgery in patients with hae-
mophilia B and in patients with liver disease [6]. Evans et
al., however, reported zero thrombotic events in 59
patients from three studies where PCCs were used to
reverse warfarin and estimated the upper 95% confidence
interval for thrombosis post-PCC treatment to be 6% or 1
in 16 [7]. As always, a risk benefit decision has to be made
for each patient, but, in the presence of major bleeding or
emergency surgery, the benefits are likely to always exceed
the small risk of thrombosis. No evidence of thromboem-
bolic complications were seen in the two patients
reported with multiple risk factors for developing such
adverse events.
The optimal method for returning the INR to the desired
range depends upon its degree of initial elevation and
whether or not clinically significant bleeding is present.
Recommendations have been elaborated by the American
College of Chest Physician Consensus Conference and
others [1,2] which are based on studies that use the ele-
vated INR as a surrogate marker for the risk of bleeding.
Most of the evidence has been obtained for anticoagula-
tion with warfarin with evidence for phenprocoumon
being less well established [2]. Evidence on treatment of
patients who present with elevated INR and who have
major bleeding are based mainly on observational stud-
ies. Treatment includes withholding oral anticoagulants,
administering intravenous vitamin K, and transfusion of
coagulation factor concentrates (Table 1). Coagulation
factor replacement in combination with vitamin K ther-
apy is currently recommended in patients with coumarin-
associated major bleeding or with indication for immedi-
ate correction of their INR [2,5]. PCCs contain coagulant
factors II, VII, IX, and X and can reverse the effect of cou-
marin more rapidly than fresh-frozen plasma in cou-
marin-related coagulopathy [10-14]. The PCC used in our
patients (Uman Complex; Kedrion Spa., Castelvecchio
Pascoli, Italy) contains factors II, IX and X, and reversed
the INR to levels allowing emergency surgery at about 1.5.
Other PCCs contain also factor VII (e.g. Beriplex P/N; ZLB
Behring, Marburg) and may offer faster achievement of
full anticoagulant reversal in even a smaller period of
time.
In conclusion, vitamin K1 antagonist-associated coagulop-
athy is commonly encountered and is particularly associ-
ated with bleeding in the elderly [4]. Avoiding over-
anticoagulation and reducing periods of overdosing in the
course of oral anticoagulant treatment may help to mini-
mise the risk of bleeding. Evidence on treatment of
patients who present with elevated INR and who have
major bleeding are based mainly on observational stud-
ies. Randomized clinical trials that measure the usefulness
of interventions by clinical mortality and morbidity
(bleeding and thrombosis) endpoints are required and
under way. Optimal treatment, including the use of oral
vitamin K1 in the asymptomatic patient, and intravenous
vitamin K1  in concert with coagulation factors in the
bleeding patient, should reduce the mortality associated
with this condition.
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